Coverage of our peer-reviewed research in the healthcare and mainstream press.
The National Pharmaceutical Council’s daily newsletter e-mail on January 5 highlighted a news article by The American Journal of Managed Care® (AJMC®)'s Surabhi Dangi-Garimella, PhD. The article, “HTA Study Raises Questions on Real-World Benefits of Newly Approved Cancer Drugs,” examined the findings of a retrospective study in JAMA Oncology that “analyzed health technology assessment reports for 62 new anticancer drugs approved in Europe and the United States” in a 10-year timeframe. It indicated that real-world benefits like overall survival vary widely by drug and by disease type.
A recent AJMC® infographic, “Making Sense of MACRA,” which summarized the timelines and options associated with the Quality Payment Program established under the Medicare Access and CHIP Reauthorization Act (MACRA), was cited in an EHR Intelligence article, “Avoiding Financial Implications of Quality Payment Program.” In the article, author Sara Heath used the infographic’s timeline to explain how physicians can avoid negative payment adjustments under the new rule.
A Watchdog article imploring readers to “Meet the Nonprofit That Helps State Governments Ration Your Health Care” profiled the Institute for Clinical and Economic Review (ICER). Author Johnny Kampis quoted an interview between Dangi-Garimella, of AJMC®'s Evidence-Based Oncology™, and ICER president and founder Steven Pearson, MD, MSc, FRCP, in which he discussed the group’s payer-focused framework.
In an article by Vera Gruessner, Health Payer Intelligence summarized the findings of a study from the recent Evidence-Based Diabetes Management™ special issue with the American Association of Diabetes Educators. The research, “Diabetes Educators in Accountable Care Organizations: Meeting Quality Measures Through Diabetes Self-Management Education and Care Coordination,” explained how diabetes educators can be a valuable resource in managing this chronic disease.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
ERISA Industry Committee Sues Minnesota Over PBM Law
January 3rd 2025The Employee Retirement Income Security Act (ERISA) Industry Committee filed a legal challenge against the Minnesota Department of Commerce, arguing that Minnesota’s Pharmacy Benefit Manager (PBM) Licensure and Regulation Act illegally interfered with employer-sponsored health plans by restricting plan design options and increasing costs.
Read More
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More